Therefore, exploring new biomarkers to identify high-risk CKD patients prone to CRS-4 becomes the hotspot, such as asymmetric dimethylarginine (ADMA) [33], nonoxidized parathyroid hormone (PTH) [34], sST2 and Gal-3 [25]. The gene discussed is PTH; the disease is craniosynostosis 4.